COMPARISON OF THE DURATION OF EFFECT OF TWO HYALURONIC ACIDS IN KNEE OSTEOARTHRITIS

Santa Lucía General University Hospital, Department of Hospital Pharmacy, Cartagena, Spain.

Background
Viscosupplementation consists of intra-articular infiltration of hyaluronic acid (HA) to improve viscosity, reduce inflammation and relieve pain in patients with knee osteoarthritis.

Purpose
To compare the percentage of patients who have required more than one dose of sodium hyaluronate (AdantOne®) versus more than one dose of hylan G-F-20 (SynviscOne®) in the same knee in less than a year.

Material and methods
Retrospective observational study including all patients with knee osteoarthritis who were treated with HA between February 2013 and October 2016.

This period was divided into 2 stages

First stage: February 2013 – January 2015 (24 months)
the HA available was AdantOne®

Second stage: February 2015 – October 2016 (21 months)
the HA available was SynviscOne®

Variables analyzed were: number of patients, dispensed units, date of infiltration, medical service
from the Hospital Pharmacy software program (Savac®) and the medical records program (Selene®)

Results

First stage
AdantOne® was dispensed to 944 patients

138 (14.62%) Rheumatology
789 (83.58%) Traumatology
17 (1.80%) Rehabilitation

72 patients (7.63%) required ≥ 2 doses of HA in the same knee in less than a year

8 (11.11%) Rheumatology
1 (1.39%) Rehabilitation
63 (87.50%) Traumatology

Second stage
SynviscOne® was dispensed to 1193 patients

137 (11.48%) Rheumatology
1039 (87.09%) Traumatology
17 (1.43%) Rehabilitation

91 patients (7.63%) required ≥ 2 doses of HA in the same knee in less than a year

13 (14.29%) Rheumatology
78 (85.71%) Traumatology

Conclusion
- The percentage of patients who have required more than one dose was the same with the two presentations of HA. However, the second stage was shorter than the first suggesting that the duration of the effect of SynviscOne® is less than the duration of AdantOne®.
- Our results show that the percentage of patients that have required two or more doses of HA in the same knee in a time period of less than one year is not very high.
- These results along with the price are important in the selection of HA.